Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

Evaluation of the Impact of a Nurse-led Telephone Follow-up on Treatment Compliance of Patients Treated From a Locally Advanced or Metastatic Non-small-cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) Mutation(s).The PARTAGE Study.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02483416
• Other study ID #: 1200.227
• Status: Terminated
• Start date: November 19, 2015
• Est. completion date: February 27, 2017

Study information

• Verified date: October 2018
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study will take place over a period of 27 months. The recruitment phase will last approximately 24 months and each patient will participate for approximately 3 months.

At the inclusion visit (D0), the investigator will ask the patient whether he would like to participate in the study and will obtain his written consent.

Patients agreeing to participate will be randomised (3:1 ratio) and included in one of the following 2 groups:

Group without `remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team (100 patients).

Group with `remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team (300 patients).

All the patients will be seen according to normal practice by the study medical team.

Patients in the group with `remote additional personalised nurse-led follow-up will be contacted 8 times during the study (at D1, D7, D14, D21, D28, D44, D59 and D89). The nurse will make sure that the treatment takes place in good conditions; she cannot intervene in the medical care of the patient, nor give answer to the questions relative to the disease or to the treatment of the patient. The medical team remains the privileged contact of the patient.

Description:

Purpose:

Study Design:

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 30
• Est. completion date: February 27, 2017
• Est. primary completion date: February 27, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion criteria:

Male or female patient older than 18 years. Adult patient diagnosed with stage IIIb/IV NSCLC locally advanced or metastatic, with activating mutation(s) of EGFR and who is EGFR-TKI naïve.

Patient for whom a decision of treatment with afatinib monotherapy has been taken in the frame of its marketing authorization.

Out-patient. Patient having given written consent for participation in the study. Patient who is able to participate in the investigator's opinion. Patient affiliated with the French social security.

Exclusion criteria:

Patients participating in an interventional clinical study. Patients for whom a participation in an interventional clinical study is foreseen within 3 months following the study inclusion.

Patients participating in a therapeutic education program.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Locations

Country	Name	City	State
France	CLI Dr Calabet, Oncolgie, Agen	Agen
France	CLI Polyclinique du Parc Rambot, Pneumo, Aix en Provence	Aix en Provence
France	HOP Centre Hospitalier Pays d'Aix, Pneumo, Aix en Provence	Aix en Provence cedex 1
France	HOP Centre Marie Curie, Onco, Arras	Arras
France	HOP Centre Hospitalier de Béziers, Pneumo, Béziers	Béziers
France	CLI Bordeaux Nord Aquitaine	Bordeaux
France	CLI Tivoli	Bordeaux
France	CH, Oncologie, Brive la Gaillarde,	Brive La Gaillarde cedex
France	HOP Louis Pradel	Bron cedex
France	CLI du Parc, Pneumo, Castelnau le Lez	Castelnau le lez
France	Centre médical N de Pontoux, Oncologie, Chalon sur Saône	Chalons Sur Saône
France	HOP de Chauny	Chauny
France	Centre Hospitalier Intercommunal, Oncolgie, Crétail	Creteil cedex
France	HOP La Dracénie, Onco, Draguignan	Draguignan
France	HOP CHD La Roche sur Yon - Montaigu - Luçon, Pneumo	La Roche Sur Yon cedex
France	HOP CH Emile Roux Le Puy, Pneumo, Le puy en Velay	Le Puy en Velay
France	HOP Hôpital Robert Boulin, Pneumo, Libourne	Libourne
France	Hopital Privé Jean Mermoz	Lyon
France	HOP Saint Joseph et Saint Luc, Pneumo, Lyon	Lyon cedex 07
France	CHG, Oncologie, Meaux	Meaux cedex
France	CLI Clémentville	Montpellier
France	HOP Centre Hospitalier de Mulhouse, Pneumo, Mulhouse	Mulhouse
France	CTR d'Oncologie de Gentilly, Onco, Nancy	Nancy
France	CLI Polyclinique le Languedoc, Narbonne	Narbonne
France	CLI Polyclinique le Languedoc, Narbonne	Narbonne cedex
France	CLI Saint-Pierre, Oncologie, Perpignan	Perpignan
France	CHR d'Annecy, Oncologie, Annecy	Pringy
France	HOP Cornouaille, Pneumo, Quimper	Quimper
France	CLI Les Bleuets, Pneumologie, Reims	Reims
France	HOP Centre Hospitalier de Saint Quentin, Pneumo, St-Quentin	Saint-Quentin cedex
France	HOP Hôpitaux du Léman	Thonon les Bains
France	HOP HIA Saint-Anne	Toulon
France	CLI Pasteur	Toulouse
France	CLI Pasteur	Toulouse
France	Centre de Radiothérapie Marie Curie	Valence
France	HOP Nord Ouest de Villefranche, oncologie, Gleize	Villefranche sur Saône Cedex

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Cumulated Dose Milligram (mg) of Oral Targeted Therapy During the 3-month Follow-up.	The cumulated dose (mg) of oral targeted therapy taken between visits is the sum of the doses (mg) of the tablets taken by the patient. The cumulated dose (mg) of the oral targeted therapy taken during the 3-month follow-up is the sum of the doses (mg) cumulated taken between visits during the 3-month follow-up.	3 months
Secondary	Score (0-6) Obtained With the Girerd Questionnaire	Girerd questionnaire is a questionnaire composed of 6 binary questions (yes/no) and is used to assess treatment compliance. The final score obtained is the number of questions to which the patient responded "yes". Thus, the score ranges from 0 to 6. A patient will be classified as: Good compliant with score = 0. Minor non-compliant with score = 1 or 2. Non-compliant with score >2.	at Day 30 (D30), Day 60 (D60) and Day 90 (D90)
Secondary	Cumulated Dose of Oral Targeted Therapy Not Taken (All Categories) Following Decision of the Medical Team	The cumulated dose (mg) of oral targeted therapy not taken between 2 visits is the sum of the doses (mg) of tablets not taken by the patient. The cumulated dose (mg) of oral targeted therapy not taken during the 3-month follow-up is the sum of the cumulated doses (mg) not taken between 2 visits during the 3-month follow-up.	3 months
Secondary	Cumulated Dose of Oral Targeted Therapy Not Taken Due to Dose Reduction Following Decision of the Medical Team.	Cumulated dose of oral targeted therapy not taken due to dose reduction following decision of the medical team.; There were no participants with dose reduction hence the data is not available.	3 months
Secondary	Cumulated Dose of Oral Targeted Therapy Not Taken Due to Temporary or Definitive Interruption Following the Medical Team Decision.	Cumulated dose of oral targeted therapy not taken due to temporary or definitive interruption following the medical team decision.	3 months
Secondary	Cumulated Dose of Oral Targeted Therapy Not Taken (All Categories) Following Patient Decision.	Cumulated dose of oral targeted therapy not taken (all categories) following patient decision. Cumulated dose not taken in total is missing since no patient without therapy following patient decision	3 months
Secondary	Cumulated Dose of Oral Targeted Therapy Not Taken Due to Dose Reduction Following Patient Decision.	Cumulated dose of oral targeted therapy not taken due to dose reduction following patient decision. No participants with dose reduction.	3 months
Secondary	Cumulated Dose of Oral Targeted Therapy Not Taken Due to Temporary or Definitive Interruption Following Patient Decision.	Cumulated dose of oral targeted therapy not taken due to temporary or definitive interruption following patient decision.; No patient without therapy following patient decision	3 months
Secondary	Visual Analogue Scale (VAS) Score (0-10) for Overall Patient Satisfaction With the Level of Care (Information, Advice) at D90.	VAS scores will be presented in the form of a horizontal ungraduated line of 10 centimeters (cm), with the following extremities: left, 'completely unsatisfied' and right, 'very satisfied'. The number of points (0 to 10) obtained in VAS corresponds to the distance (cm) between the left extremity of the line and the mark placed on the line by the patient, investigator, general practitioner, or pharmacist to assess patient's level of satisfaction.	3 months
Secondary	Change in Quality of Life Questionnaire Functional Assessment of Cancer Therapy Lung (FACT-L) Score Between D30 and D0, Between D90 and D30 and Between D90 and D0	The patients' quality of life was evaluated with the FACT-L questionnaire. This questionnaire explores 4 dimensions of well-being: physical, social and emotional. These items are completed by 9 questions specific to lung cancer. Subscale scores are added to obtain total score. Scores obtained with this questionnaire range between 0 and 136. The higher the score the better the quality of life.	Day0 (D0), Day30 (D30) and Day90 (D90)
Secondary	Number of Emergency Admissions (Related to the Treatment) During the 3-month Follow-up.	Number of participants with emergency admissions (related to the treatment) during the 3-month follow-up are presented	Day30 (D30), Day60 (D60) and Day90 (D90)
Secondary	Number of Unplanned Hospitalizations (Related to the Treatment) During the 3-month Follow-up	Number of participants with unplanned hospitalizations (related to the treatment) during the 3-month follow-up is presented	D30, D60, D90
Secondary	Duration of Unplanned Hospitalizations (Related to the Treatment)) During the 3-month Follow-up.	Duration of unplanned hospitalizations (related to the treatment) during the 3-month follow-up are presented	D30, D60 and D90
Secondary	Number of Unplanned Visits to the Investigator During the 3-month Follow-up	Number of participants with unplanned visits to the investigator during the 3-month follow-up are presented	D30, D60 and D90
Secondary	Number of Unplanned Visits to a Specialist, Whatever is His Specialty, Other Than the Investigator During the 3-month Follow-up.	Number of participants with unplanned visits to a specialist, whatever is his specialty, other than the investigator during the 3-month follow-up is presented	D30, D60 and D90
Secondary	Number of Unplanned Visits to the General Practitioner During the 3-month Follow-up	Number of participants with unplanned visits to the general practitioner during the 3-month follow-up is presented	D30, D60 and D90
Secondary	VAS Score (0-10) for Overall Investigator Satisfaction With the Level of Patient Care at D90	VAS score (0-10) for overall investigator satisfaction with the level of patient care at D90 (Overall investigator satisfaction) is presented.; VAS scores will be presented in the form of a horizontal ungraduated line of 10 centimeters (cm), with the following extremities: left, 'completely unsatisfied' and right, 'very satisfied'. The number of points (0 to 10) obtained in VAS corresponds to the distance (cm) between the left extremity of the line and the mark placed on the line by the patient, investigator, general practitioner, or pharmacist to assess patient's level of satisfaction.	D90
Secondary	VAS Score (0-10) for Overall General Practitioner Satisfaction With the Level of Patient Care at D90 (Only for the Patients With 'Remote Additional Personalised Nurse-led Follow-up)	VAS score (0-10) for overall general practitioner satisfaction with the level of patient care at D90 (only for the patients with 'remote additional personalised nurse-led follow-up) (Overall general practitioner satisfaction) is presented.; VAS scores will be presented in the form of a horizontal ungraduated line of 10 centimeters (cm), with the following extremities: left, 'completely unsatisfied' and right, 'very satisfied'. The number of points (0 to 10) obtained in VAS corresponds to the distance (cm) between the left extremity of the line and the mark placed on the line by the patient, investigator, general practitioner, or pharmacist to assess patient's level of satisfaction.	D90
Secondary	VAS Score (0-10) for Overall Pharmacist Satisfaction With the Level of Patient Care at D90 (Only for the Patients With 'Remote Additional Personalised Nurse-led Follow-up).	VAS score (0-10) for overall pharmacist satisfaction with the level of patient care at D90 (only for the patients with 'remote additional personalised nurse-led follow-up)(Overall pharmacist satisfaction) is presented.; VAS scores will be presented in the form of a horizontal ungraduated line of 10 centimeters (cm), with the following extremities: left, 'completely unsatisfied' and right, 'very satisfied'. The number of points (0 to 10) obtained in VAS corresponds to the distance (cm) between the left extremity of the line and the mark placed on the line by the patient, investigator, general practitioner, or pharmacist to assess patient's level of satisfaction.	D90
Secondary	Number of Calls Made by the Patients to Their General Practitioner During the 3-month Follow-up.	Number of calls made by the patients to their general practitioner during the 3-month follow-up is presented	D30, D60 and D90
Secondary	Number of Calls Made by the General Practitioner to the Patient During the 3-month Follow-up.	Number of calls made by the general practitioner to the patient during the 3-month follow-up is presented	D30, D60 and D90
Secondary	Number of Calls Made by the Patients to Their Medical Team During the 3-month Follow-up	Number of calls made by the patients to their medical team during the 3-month follow-up is presented	D30, D60 and D90
Secondary	Number of Calls Made by the Medical Team to Their Patient During the 3-month Follow-up	Number of calls made by the medical team to their patient during the 3-month follow-up is presented	D30, D60 and D90
Secondary	Number of Calls Between the General Practitioners and the Medical Teams During the 3-month Follow-up	Number of calls between the general practitioners and the medical teams during the 3-month follow-up is presented	D30, D60, D90
Secondary	Number of Adverse Events (AEs), of AEs of Grade = 3, of SAEs Related to the Oral Biological Therapy and Number of AEs Related to the Oral Targeted Therapy Which Causes Temporary or Definitive Discontinuation of the Treatment or Dose Reduction.	Number of participants with Adverse events AEs, of AEs of grade = 3, of serious adverse events (SAEs) related to the oral biological therapy and Number of AEs related to the oral targeted therapy which causes temporary or definitive discontinuation of the treatment or dose reduction are presented	up to 3 months

External Links

•   Link